Onconova Therapeutics, Inc.

Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics fourth quarter and full year 2022 financial results and business update conference call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a question and answer session. To ask a question at that time, please press star followed by the number one on your touchtone phone. If anyone has any difficulty hearing the conference, please press star zero for operator assistance. As a reminder, this call is being recorded today, March 16th, 2023. At this time, I would like to turn the call over to Bruce Mackle of Lifestyle Advisors.

Thank you, operator, and welcome everyone to Oncanova's fourth quarter and full year 2022 financial results and business update conference call. Earlier this afternoon, Oncanova issued a press release reporting its financial results and business progress. If you have not seen this press release, it is available in the Investors and Media section of the company's website at Ancanova.com. Following my introduction, we will hear from Ancanova's President and CEO, Dr. Steve Fruchman, Chief Medical Officer, Dr. Mark Gelder, and Chief Operating Officer and Chief Financial Officer, Mark Guerin. These prepared remarks will then be followed by a question and answer session. Before we begin, I would like to remind everyone that made during this conference call will include forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, which involve and uncertainties that can cause actual results to differ materially. Forward-looking statements speak only as the date they are made, as the underlying facts and circumstances may change. Except as required by law, Ankanova disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances. For more information on forward-looking statements, please review the disclaimer in today's press release and the risk factors in the company's SEC filings. With that, I will now turn the call over to Ankanova's President and CEO, Dr. Steve Fruchman.

Thank you, Bruce, and thanks to all who have joined the call today.